Subacute cutaneous lupus erythematosus induced by nivolumab

Australasian Journal of Dermatology, Journal Year: 2017, Volume and Issue: 59(2)

Published: July 20, 2017

Language: Английский

---

Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity

Journal of Controlled Release, Journal Year: 2018, Volume and Issue: 289, P. 125 - 145

Published: Sept. 14, 2018

Language: Английский

---

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview

Current Drug Safety, Journal Year: 2019, Volume and Issue: 14(1), P. 14 - 20

Published: Jan. 17, 2019

Background: The introduction of Immune Checkpoint Inhibitors in the recent years has resulted high response rates and extended survival patients with metastatic/advanced malignancies. Their mechanism action is indirect activation cytotoxic T-cells through blockade inhibitory receptors immunomodulatory pathways, such as T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1) its ligand (PD-L1). Despite their impressive therapeutic results, they can also induce immune-related toxicity, affecting various organs, including skin. Objective: To provide an updated summarized overview most common immune-mediated cutaneous side effects management. Method: English articles derived from databases PubMed SCOPUS published between 2009 2018, were analyzed for this narrative review. Results: adverse reactions include maculopapular rash, lichenoid reactions, vitiligo pruritus, severity Grade 1 or 2. Less frequent but eventually life-threatening skin effects, Stevens-Johnson syndrome, Drug Reaction Eosinophilia Systemic Symptoms Toxic Epidermal necrolysis, have been reported. Conclusion: Basic knowledge Immune-Checkpoint-Inhibitors-induced toxicity necessary order to recognize these treatment-related complications. tend subside under symptomatic treatment so that permanent discontinuation therapy not commonly necessary. In case apart treatment, immunotherapy should be permanently stopped. Information concerning management ICIs-mediated obtained literature well Summary Product Characteristics each agent.

Language: Английский

---

Vitiligo-like rash in a patient with lung cancer caused by sintilimab: A case report

World Journal of Clinical Cases, Journal Year: 2025, Volume and Issue: 13(14)

Published: Jan. 14, 2025

BACKGROUND This article discusses a case involving 63-year-old man with non-small cell lung cancer, who was treated combination of chemotherapy and immunotherapy. The patient five cycles (pemetrexed carboplatin) combined sintilimab, programmed death 1 inhibitor. CASE SUMMARY After the fifth cycle treatment, developed skin itching vitiligo-like rash, which are known side effects Despite dermatological consultation treatment topical corticosteroids, rash worsened while subsided. continued after 15 cycles, tumor showed response reduction in size. increased, but antitumor remained effective. CONCLUSION highlights use immunotherapy patients cancer potential effect rash. patient’s responded well to despite reaction, not discontinued due its effectiveness. suggests that further studies needed understand mechanism behind vitiligo receiving immune checkpoint inhibitors whether development inhibitor therapy is associated improved prognosis. also underscores importance managing immune-related adverse events context effective treatment.

Language: Английский

---

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management

Therapeutic Advances in Medical Oncology, Journal Year: 2018, Volume and Issue: 10

Published: Jan. 1, 2018

The anti-programmed cell death-1 (PD-1) and death ligand-1 (PD-L1) immunotherapies have shown exceptional activity in many cancers. However, these can also result diverse adverse cutaneous eruptions that need to be better characterized for ongoing management. objective was provide clinical histopathologic descriptions of the variety events seen patients who received anti-PD-1/PD-L1 treatment discuss their management.Patients with advanced cancers trials at University California Los Angeles (UCLA), receiving between 2012 2016 developed were evaluated dermatology clinic included this retrospective case series study. A total 16 study; these, five treated pembrolizumab alone, two avelumab eight nivolumab plus ipilimumab one T-Vec. Of patients, had systemic chemotherapy, six radiotherapy, trememlimumab prior described study.Cutaneous occurred variable times, from week 1 88, a median 11.5 weeks; morphologies lichenoid, bullous, psoriasiform, macular, morbiliform appearances, alopecia which confirmed histopathologically several cases. All immune-related either grade or 2. Ten topical corticosteroids, NBUVB. Four eventually required steroids. Three discontinuation therapy secondary eruptions.There are different types may administration PD-1 PD-L1 inhibitors. Identifying patterns eruption assist prompt treatment. Most could managed corticosteroids without

Language: Английский

---

Pruritus Associated with Targeted Anticancer Therapies and Their Management

Dermatologic Clinics, Journal Year: 2018, Volume and Issue: 36(3), P. 315 - 324

Published: June 18, 2018

Language: Английский

---

Biologic response modifiers: Indications, implications, and insights

Journal of Allergy and Clinical Immunology, Journal Year: 2017, Volume and Issue: 139(5), P. 1445 - 1456

Published: March 2, 2017

Language: Английский

---

Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors

Advances in Dermatology and Allergology, Journal Year: 2019, Volume and Issue: 36(4), P. 382 - 391

Published: Jan. 1, 2019

ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Kamińska-Winciorek G, Cybulska-Stopa B, Ługowska I, Ziobro M, Rutkowski P. Principles of prophylactic and therapeutic management skin toxicity during treatment with checkpoint inhibitors. Advances in Dermatology Allergology/Postępy Dermatologii i Alergologii. 2019;36(4):382-391. doi:10.5114/ada.2018.80272. APA Kamińska-Winciorek, G., Cybulska-Stopa, B., Ługowska, I., Ziobro, M., & Rutkowski, (2019). Alergologii, 36(4), 382-391. https://doi.org/10.5114/ada.2018.80272 Chicago Grażyna, Bożena Iwona Marek Piotr Rutkowski. 2019. "Principles inhibitors". Alergologii 36 (4): Harvard pp.382-391. MLA Grażyna et al. inhibitors." vol. 36, no. 4, 2019, pp. Vancouver

Language: Английский

---

Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences

American Journal of Clinical Dermatology, Journal Year: 2020, Volume and Issue: 21(5), P. 669 - 680

Published: May 28, 2020

Language: Английский

---

Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab)

Current problems in dermatology, Journal Year: 2017, Volume and Issue: unknown, P. 82 - 92

Published: Nov. 7, 2017

With increasing use of immunotherapies such as anti-cytotoxic T cell lymphocyte antigen-4 and anti-programmed death 1 antibodies, various skin toxicities have emerged. Severity varies from mild lichenoid reaction to severe toxic epidermal necrolysis. Appropriate diagnosis management these are essential for optimal patient care avoid unnecessary cessation anti-cancer therapies. This review summarises a wide range cutaneous manifestations associated with immunotherapy usage in patients metastatic melanoma.

Language: Английский

---